Rigel Pharmaceuticals, Inc.
(NASDAQ : RIGL)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -0.60%163.540.7%$1305.95m
LLYEli Lilly & Co. -1.93%323.651.1%$1056.02m
ABBVAbbVie, Inc. -5.84%134.381.9%$793.06m
PFEPfizer Inc. -0.75%43.830.9%$778.51m
BMYBristol-Myers Squibb Co. -0.82%71.121.0%$763.08m
MRKMerck & Co., Inc. -0.52%86.190.7%$687.90m
AZNAstraZeneca Plc -0.13%54.841.0%$411.81m
NVSNovartis AG -0.73%76.010.2%$216.26m
GSKGSK Plc 0.31%29.450.3%$214.53m
ALNYAlnylam Pharmaceuticals, Inc. -4.41%200.168.2%$210.64m
GBTGlobal Blood Therapeutics, Inc. 0.04%68.105.4%$190.73m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. -0.21%151.220.0%$178.64m
IDXXIDEXX Laboratories, Inc. -1.81%325.803.9%$175.84m
HZNPHorizon Therapeutics Plc -1.28%61.895.4%$160.55m
NVONovo Nordisk A/S -0.74%99.650.1%$140.44m

Company Profile

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.